Moreover, Scher and colleagues showed that CTC expression of SLFN11 in patients with advanced PCa supported the predictive role of SLFN11 expression in selecting patients who may benefit from platinum chemotherapy and PARPi [98]. Here, SLFN11 is linked to posterior cortical atrophy.